This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (DF/HCC# 22-175) and NCT06026319 (DF/HCC# 23-474).
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Overall Survival
Timeframe: 1 month
Overall Survival
Timeframe: 6 months
Overall Survival
Timeframe: 12 months
Overall Survival
Timeframe: 24 months
Progresison Free Survival
Timeframe: 1 month
Progresison Free Survival
Timeframe: 6 months
Progresison Free Survival
Timeframe: 12 months
Progresison Free Survival
Timeframe: 24 months
New incidence or exacerbation of a pre-existing neurologic disorder or prior rheumatologic or other autoimmune disorder
Timeframe: Up to 15 Years
New incidence of a hematologic disorder
Timeframe: up to 15 years
Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v 5.0
Timeframe: up to 15 years
Vector-derived RCL
Timeframe: baseline and in 3 months, 6 months, and annually up to 15 years
Assessment of CAR T cells persistence by VCN in peripheral blood
Timeframe: baseline and in 3 months, 6 months, every 6 months up to 5 years, and annually up to 15 years
Progression-free Survival
Timeframe: From post-CAR T cells infusion date until date of first documented disease progression or date of death from any cause, assessed up to 15 years post treatment
Overall Survival
Timeframe: From post-CAR T cells infusion date until documented date of death from any cause, assessed post treatment every 6 months through 5 years and then annually up to 15 years